Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia

Leukemia

Volumn 29, Issue 11, 2015, Pages 2143-2153

  Dorrance, A M ^a,b   Neviani, P ^a,b   Ferenchak, G J ^a,b   Huang, X ^a,b,c   Nicolet, D ^b,d   Maharry, K S ^b,d   Ozer, H G ^b,d   Hoellarbauer, P ^a   Khalife, J ^a,b   Hill, E B ^a,b   Yadav, M ^a,b   Bolon, B N ^a   Lee, R J ^a,c   Lee, L J ^a,c   Croce, C M ^a,e   Garzon, R ^a,b,e   Caligiuri, M A ^a,b   Bloomfield, C D ^a,b   Marcucci, G ^e  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c Ohio State University   (United States)

^d MAYO CLINIC   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTAGOMIR; ANTAGOMIR 126; ANTHRACYCLINE; CYTARABINE; MICRORNA; MICRORNA 126; NANOPARTICLE; UNCLASSIFIED DRUG; CD45 ANTIGEN; MIRN126 MICRORNA, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STEM CELL; CELL RENEWAL; CELL SUBPOPULATION; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; DRUG DELIVERY SYSTEM; EVENT FREE SURVIVAL; FEASIBILITY STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LEUKEMIA STEM CELL; MAJOR CLINICAL STUDY; MIDDLE AGED; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DNA METHYLATION; DRUG EFFECTS; GENETICS; LEUKEMIA, MYELOID, ACUTE; MORTALITY; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD45; DNA METHYLATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED C57BL; MICRORNAS; NANOPARTICLES; NEOPLASTIC STEM CELLS;

EID: 84946495561     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.139     Document Type: Article

References (33)

1. Mawad R, Estey EH. Acute myeloid leukemia with normal cytogenetics. Curr Oncol Rep 2012; 14: 359-368.
2. Marcucci G, Mrozek K, Radmacher MD, Garzon R, Bloomfield CD. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 2011; 117: 1121-1129.
3. Sagar J, Chaib B, Sales K, Winslet M, Seifalian A. Role of stem cells in cancer therapy and cancer stem cells: A review. Cancer Cell Int 2007; 7: 9.
4. Sarry JE, Murphy K, Perry R, Sanchez PV, Secreto A, Keefer C et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rgammac-deficient mice. J Clin Invest 2011; 121: 384-395.
5. Heidel FH, Mar BG, Armstrong SA. Self-renewal related signaling in myeloid leukemia stem cells. Int J Hematol 2011; 94: 109-117.
6. Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Basecke J, Libra M et al. Targeting the leukemic stem cell: The Holy Grail of leukemia therapy. Leukemia 2009; 23: 25-42.
7. Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007; 110: 4427-4435.
8. Macfarlane LA, Murphy PR. MicroRNA: biogenesis, function and role in cancer. Curr Genomics 2010; 11: 537-561.
9. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775-789.
10. Havelange V, Garzon R, Croce CM. MicroRNAs: new players in acute myeloid leukaemia. Br J Cancer 2009; 101: 743-748.
11. Havelange V, Garzon R. MicroRNAs: emerging key regulators of hematopoiesis. Am J Hematol 2010; 85: 935-942.
12. Marcucci G, Radmacher MD, Mrozek K, Bloomfield CD. MicroRNA expression in acute myeloid leukemia. Curr Hematol Malignancy Rep 2009; 4: 83-88.
13. Marcucci G, Radmacher MD, Maharry K, Mrozek K, Ruppert AS, Paschka P et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1919-1928.
14. Marcucci G, Mrozek K, Radmacher MD, Bloomfield CD, Croce CM. MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias. Best Practice Res Clin Haematol 2009; 22: 239-248.
15. Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrozek K et al. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol 2013; 31: 2086-2093.
16. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008; 111: 3183-3189.
17. Lechman ER, Gentner B, van Galen P, Giustacchini A, Saini M, Boccalatte FE et al. Attenuation of miR-126 activity expands HSC in vivo without exhaustion. Cell Stem Cell 2012; 11: 799-811.
18. Alachkar H, Santhanam R, Maharry K, Metzeler KH, Huang X, Kohlschmidt J et al. SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. J Clin Invest 2014; 124: 1512-1524.
19. Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P et al. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: A novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res 2013; 19: 2355-2367.
20. Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest 2013; 123: 4144-4157.
21. Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA 2008; 105: 15535-15540.
22. Marcucci G, Yan P, Maharry K, Frankhouser D, Nicolet D, Metzeler KH et al. Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J Clin Oncol 2013; 32: 548-556.
23. Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011; 17: 1086-1093.
24. Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 2010; 120: 142-156.
25. Guan Y, Gerhard B, Hogge DE. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 2003; 101: 3142-3149.
26. Zorko NA, Bernot KM, Whitman SP, Siebenaler RF, Ahmed EH, Marcucci GG et al. Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias. Blood 2012; 120: 1130-1136.
27. Felli N, Felicetti F, Lustri AM, Errico MC, Bottero L, Cannistraci A et al. miR-126&126∗ restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. PLoS ONE 2013; 8: e56824.
28. huang HT, Lee CT, Yu S, Zon LI, Speck NA. Chromatin remodeling enzyme CHD7 negatively regulate hematopoietic stem cell function. Blood 2013; 112: 2413.
29. Poulos MG, Guo P, Kofler NM, Pinho S, Gutkin MC, Tikhonova A et al. Endothelial Jagged-1 is necessary for homeostatic and regenerative hematopoiesis. Cell Rep 2013; 4: 1022-1034.
30. Doulatov S, Notta F, Laurenti E, Dick JE. Hematopoiesis: A human perspective. Cell Stem Cell 2012; 10: 120-136.
31. de Leeuw DC, Denkers F, Olthof MC, Rutten AP, Pouwels W, Schuurhuis GJ et al. Attenuation of microRNA-126 expression that drives CD34+38-stem/progenitor cells in acute myeloid leukemia leads to tumor eradication. Cancer Res 2014; 74: 2094-2105.
32. Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 2015; 518: 107-110.
33. Velu CS, Chaubey A, Phelan JD, Horman SR, Wunderlich M, Guzman ML et al. Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. J Clin Invest 2014; 124: 222-236.